Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Мочевая кислота и сердечно-сосудистые заболевания: новый С-реактивный белок?
Мочевая кислота и сердечно-сосудистые заболевания: новый С-реактивный белок?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье обсуждается роль увеличения уровня мочевой кислоты (МК) в крови как маркера повышенного риска развития осложнений сердечно-сосудистых заболеваний. Приведены данные о связи повышенной концентрации МК в крови с артериальной гипертонией, сердечной недостаточностью, ишемической болезнью сердца. Проведена аналогия повышенного уровня МК с другим стандартным маркером повышенного риска развития осложнений сосудистых заболеваний – С-реактивным белком. Рассмотрена роль лекарственных препаратов, влияющих на уровень МК, в частности лозартана, в лечении больных артериальной гипертонией.
Ключевые слова: сердечно-сосудистые заболевания, мочевая кислота, артериальная гипертония, лозартан.
Key words: cardiovascular diseases, uric acid, arterial hypertension, losartan.
Ключевые слова: сердечно-сосудистые заболевания, мочевая кислота, артериальная гипертония, лозартан.
________________________________________________
Key words: cardiovascular diseases, uric acid, arterial hypertension, losartan.
Полный текст
Список литературы
1. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005; 118: 816–26.
2. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49: 1229–38.
3. Mazzali M, Kanbay M, Segal MS et al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010; 12: 108–17.
4. Kanbay M, Ozkara A, Selcoki Y et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227–33.
5. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924–32.
6. Høieggen A, Alderman MH, Kjeldsen SE et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9.
7. Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail 2009; 2: 556–62.
8. Strasak A, Ruttmann E, Brant L et al. Ulmer H. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008; 54: 273–84.
9. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–62.
10. Johnson RJ, Rodriguez-Iturbe B, Kang DH et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431–40.
11. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39–42.
12. Leyva F, Anker S, Swan JW et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858–65.
13. Coutinho Tde A, Turner ST, Peyser PA et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007; 20: 83–9.
14. Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1174–81.
15. Leyva F, Anker SD, Godsland IF et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814–22.
16. Olexa P, Olexova M, Gonsorcik J et al. Uric acid – a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr 2002; 114: 211–5.
17. Annemans L, Spaepen E, Gaskin M et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008; 67: 960–6.
18. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991; 34: 141–5.
19. Hillis GS, Cuthbertson BH, Gibson PH et al. Uric acid levels and outcome from coronary artery bypass grafting. J Thorac Cardiovasc Surg 2009; 138: 200–5.
20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
21. Moriarity JT, Folsom AR, Iribarren C et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136–43.
22. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9. [Erratum N Engl J Med 1997; 337: 356.]
23. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837–42.
24. Nakashima M, Uematsu T, Kosuge K. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42 (3): 333–5.
25. Ильиных Е.В. Факторы риска развития кардиоваскулярных заболеваний у больных подагрой. Автореф. дис. … канд. мед. наук. М., 2006.
26. Grossman E, Peleg E, Caroll J et al. Hemodynamic and humoral effect of the angiotensin II receptor antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041–4.
27. Shaninfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide induced hyperuricemia. Kidney Int 1999; 56: 1879–95.
28. Bardin T. Fenofibrate and losartan. Ann Rheum Dis 2003; 62: 497–8.
29. Liberopoulos E, Christed D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2002; 20 (2): 347.
30. Wallace SL, Robinson H, Masi AT et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthritis Rheum 1977; 20: 895–900.
31. W. Zang et al. EULAR evidence based recommendation for gout. Ann Rheum Dis 2006; 65: 12312–24.
32. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998; 16: 761–9.
2. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49: 1229–38.
3. Mazzali M, Kanbay M, Segal MS et al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010; 12: 108–17.
4. Kanbay M, Ozkara A, Selcoki Y et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227–33.
5. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924–32.
6. Høieggen A, Alderman MH, Kjeldsen SE et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9.
7. Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail 2009; 2: 556–62.
8. Strasak A, Ruttmann E, Brant L et al. Ulmer H. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008; 54: 273–84.
9. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–62.
10. Johnson RJ, Rodriguez-Iturbe B, Kang DH et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431–40.
11. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39–42.
12. Leyva F, Anker S, Swan JW et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858–65.
13. Coutinho Tde A, Turner ST, Peyser PA et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007; 20: 83–9.
14. Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1174–81.
15. Leyva F, Anker SD, Godsland IF et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814–22.
16. Olexa P, Olexova M, Gonsorcik J et al. Uric acid – a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr 2002; 114: 211–5.
17. Annemans L, Spaepen E, Gaskin M et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008; 67: 960–6.
18. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991; 34: 141–5.
19. Hillis GS, Cuthbertson BH, Gibson PH et al. Uric acid levels and outcome from coronary artery bypass grafting. J Thorac Cardiovasc Surg 2009; 138: 200–5.
20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
21. Moriarity JT, Folsom AR, Iribarren C et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136–43.
22. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9. [Erratum N Engl J Med 1997; 337: 356.]
23. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837–42.
24. Nakashima M, Uematsu T, Kosuge K. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42 (3): 333–5.
25. Ильиных Е.В. Факторы риска развития кардиоваскулярных заболеваний у больных подагрой. Автореф. дис. … канд. мед. наук. М., 2006.
26. Grossman E, Peleg E, Caroll J et al. Hemodynamic and humoral effect of the angiotensin II receptor antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041–4.
27. Shaninfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide induced hyperuricemia. Kidney Int 1999; 56: 1879–95.
28. Bardin T. Fenofibrate and losartan. Ann Rheum Dis 2003; 62: 497–8.
29. Liberopoulos E, Christed D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2002; 20 (2): 347.
30. Wallace SL, Robinson H, Masi AT et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthritis Rheum 1977; 20: 895–900.
31. W. Zang et al. EULAR evidence based recommendation for gout. Ann Rheum Dis 2006; 65: 12312–24.
32. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998; 16: 761–9.
Авторы
С.Р.Гиляревский, И.М.Кузьмина, Х.Р.Келехсаев
Научно-исследовательский институт скорой помощи им. Н.В.Склифосовского, Москва
N.V.Sklifosovsky Research Institute of Emergency Care
Научно-исследовательский институт скорой помощи им. Н.В.Склифосовского, Москва
________________________________________________
N.V.Sklifosovsky Research Institute of Emergency Care
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.